🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. JNJ-63723283, JNJ-63723283, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., JNJ-17000139, GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabine100 mg/ml Concentrate for Solution for Infusion, Gemcitabin Accord 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder

    phase 3 small molecule active

    1 trial

  2. JNJ-67896049, JNJ-67896049, Opsumit 10 mg film-coated tablets, JNJ-68150420, JNJ-67896049

    Lacuna Pharma Pty Ltd

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  3. JNJ-75276617, Venclyxto 100 mg film-coated tablets, matching the 100 mg (G030), matching the 30 mg (G031), Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, JNJ-75276617, JNJ-75276617, matching the 50 mg (G029), JNJ-75276617, Azacitidine betapharm 25 mg/mL powder for suspension for injection

    Janssen-Cilag International N.V.

    Acute Myeloid Luekemia

    phase 3 small molecule active

    1 trial

  4. JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  5. JNJ-77242113, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib, DEUCRAVACITINIB

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  6. JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  7. JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  8. JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  9. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  10. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Sjögren's Disease

    phase 3 small molecule active

    1 trial

  11. JZP598, GEMCITABINE , TRASTUZUMAB , CAPECITABINE , VINORELBINE , ERIBULIN

    Jazz Pharmaceuticals Ireland Limited

    Metastatic HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  12. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  13. Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets

    Boehringer Ingelheim

    Chronic kidney disease in paediatric patients

    phase 3 small molecule active

    1 trial

  14. Jaypirca 100 mg film-coated tablets, BGB-16673, BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

    phase 3 small molecule active

    1 trial

  15. Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  16. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets

    Alfasigma S.p.A.

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  17. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

    Alfasigma S.p.A.

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  18. Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets, GLPG0634

    Alfasigma S.p.A.

    Polyarticular-course juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  19. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

  20. KALOMIN™ Tab.

    United Therapeutics Europe Ltd

    Acute Bronchitis

    phase 3 small molecule completed

    1 trial

  21. KARDEGIC 75 mg, poudre pour solution buvable en sachet-dose, CLOPIDOGREL, CLOPIDOGREL

    ISTA Pharma Limited

    chronically occluded coronary artery

    phase 3 small molecule active

    1 trial

  22. KETAMINE RENAUDIN 50 mg/ml, solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab)

    Arcus Biosciences

    Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources